AccuMetab™ Human CYP2C8 Enzyme, Catalytically Active

CAT#: ITS-0426-YL9
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2C8 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP2C8 plays a crucial role in the oxidation of large, therapeutic molecules such as paclitaxel and various antidiabetic drugs. ADME screening against this enzyme is necessary to flag unique inhibitory drug-drug interactions that are often missed when focusing solely on the major CYP3A or 2D6 pathways.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Optimized for large, bulky therapeutic molecules; Essential for paclitaxel and amodiaquine clearance
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME, Drug-Drug Interactions (DDI), Toxicology
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry